Apellis stock drops on Astellas drug update By Investing.com
skylinenews Investing.com — Shares of Apellis Pharmaceuticals (NASDAQ:) fell 8.9% in premarket trading following news that the FDA accepted a revised…
Read MoreApellis
Investing.com — Shares of Apellis Pharmaceuticals (NASDAQ:) fell 8.9% in premarket trading following news that the FDA accepted a revised…
Read More